Status: Not yet recruiting
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.
Participants needed: 100
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.Updated: Oct 21, 2024Locations: 1
Eligibility criteria
The subjects voluntarily joined this study, signed an informed consent form, and... [+6]
Has experienced or currently has other malignant tumors within the past 5 years... [+17]